echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > IBD: Endocyte biomarkers predict the response of Crohn's disease to biological agents.

    IBD: Endocyte biomarkers predict the response of Crohn's disease to biological agents.

    • Last Update: 2020-10-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Biologics are antibody drugs for specific inflammatory pathways and are now widely used to treat moderate to severe inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC).
    IBD is a group of heterogeneic diseases whose disease esopathy and clinical course vary greatly, and patients may react differently to each biological category depending on their specific disease subtype.
    Despite the widespread clinical use of anti-TNF therapy, nearly half of CD patients did not experience the desired clinical response after receiving biologics, resulting in a sharp increase in health care costs, with no significant improvement in results.
    So far, much of the work has focused on identifying and validating biomarkers that predict anti-TNF treatment responses, and recent studies have found that micro-fluff gene expression play a role in the pathogenesis of mucosal inflammation, a common change in CD patients.
    Previously identified mucous membrane biomarkers called refleous microflue length (MVL) read well gene expression data, and studies have shown significantly lower expression of intestinal MVL in patients with disease-active CD, so this study aims to explore the clinical effects of epithelocellular biomarker reflegment micro-fluff length (MVL) on patients with utekinumab (UST) and vedolizumab (VDZ).
    MVL analysis of intestinal biopsies from CD patients in a randomized controlled trial to predict clinical responses to UST and VDZ treatments.
    the researchers assessed the correlation between intestinal MVL and endocystress (IEC) and examined the ability of the two biomarkers to judge the effectiveness of VDZ therapy.
    that the clinical response of UST was significantly higher than that of placebo (65% VS 39% ;P s 0.03) and that patients with normal MVL (sgt; 1.7 sm) had better therapeutic results (85% VS 20% ;P s 0.02).
    for VDZ, the clinical remission rate of MVL of 1.35 to 1.55 m was 82%, and the therapeutic effect of MVL was only 44% for the treatment of the MVL of .lt;1.35 μm and only 40% for the treatment effect of the MVL of .gt; 1.55 m .M.
    there was no correlation between intestinal MVL and IEC.
    patients with CD with an intestinal MVL of 1.35 to 1.55 m had an 84% effective rate of UST treatment (P - 0.001).
    , the researchers said the length of the intestinal MVL predicts how CD people react to UST and VDZ.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.